Originally approved to help manage type 2 diabetes, it has since been approved for weight loss
A liquid chromatography-tandem mass spectroscopy/mass spectroscopy (LC-MS/MS) assay was used following precipitation of the plasma proteins (Celerion Switzerland AG, Fehraltorf, Switzerland)
Visible Particles: If you see tiny white flakes, crystals, or clumps floating in the liquid, do not use it
When combined, patients may experience: Excessive appetite suppression , leading to inadequate caloric intake Unintended weight loss beyond therapeutic targets Nutritional deficiencies if dietary intake becomes severely restricted Difficulty maintaining energy for daily activities Hypoglycemia risk in patients also taking insulin or sulfonylureas, due to reduced food intake Gastrointestinal effects may also be compounded
Other important risks include acute pancreatitis, gallbladder disease (including cholelithiasis and cholecystitis), acute kidney injury (particularly in patients experiencing severe gastrointestinal symptoms), hypoglycemia when used with insulin or insulin secretagogues, increased heart rate, diabetic retinopathy complications in patients with diabetes, and suicidal behavior or ideation
